igrt for cervical cancer feb 8 2013 920 a cancer ci 2013
TRANSCRIPT
![Page 1: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/1.jpg)
IGRT for Gyn Cancer?
Akila N. Viswanathan, MD MPHBrigham and Women’s/Dana-Farber
Cancer CenterHarvard Medical School
![Page 2: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/2.jpg)
Why use IGRT in Gyne?
• Decrease toxicity
• Dose escalation
• Most important area for IGRT is in image guided brachytherapy
![Page 3: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/3.jpg)
Major Issues with IMRT/IGRT
• Need for continual replanning given rapid regression of tumor
• High margin for error with tight margins
• Increase in integral dose
• Longer treatment times
![Page 4: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/4.jpg)
Indications for IMRT/IGRT Cervix
• Nodal involvement (pelvic or PAN) – Maximize boost dose
• Para-aortic node treatment– Reduce small bowel dose
• Boost sidewall in region inaccessible to brachytherapy
• Recurrence in radiated area (re-irradiation)• NOT for routine treatment• NOT a replacement for brachytherapy
![Page 5: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/5.jpg)
Mobile uterus, Cervix, Normal Tissues
![Page 6: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/6.jpg)
Decrease tumor size @1cm/week
![Page 7: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/7.jpg)
Uterus Contouring
• ? Include whole uterus
−Account for motion?
−Varies with bladder filling
−Hard to know where cervix ends and uterus begins
![Page 8: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/8.jpg)
Movement of cervix on CTBeadle et al IJROBP 2009;73:235-41
• Center of the cervix:– 2.1 cm superior-inferior – 1.6 cm anterior-posterior– 0.82 right-left lateral
Mean maximum changes in the perimeter of the cervix:
2.3 cm and 1.3 cm in the superior and inferior
1.7 cm in the anterior, 1.8 cm in the posterior
0.76 and 0.94 cm in the right and left lateral
![Page 9: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/9.jpg)
Movement on CT
• Haripotepornkul NH, Nath SK, Scanderbeg D, Saenz C, Yashar CM. Evaluation of intra- and inter-fraction movement of the cervix during intensity modulated radiation therapy. Radiother Oncol 2011;98:347-51
• Tyagi N, Lewis JH, Yashar CM, et al. Daily online cone beam computed tomography to assess interfractional motion in patients with intact cervical cancer. Int J Radiat Oncol Biol Phys 2011;80:273-80
• Within and between radiation treatments, cervical motion averaged approximately 3mm in any given direction with maximal movement of the cervix up to 18 mm from baseline
![Page 10: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/10.jpg)
In addition to movement, must account for errors in
contouring
![Page 11: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/11.jpg)
RTOG consensus on contouring the CTV for intact cervix patients
![Page 12: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/12.jpg)
(12/10)
Background & AimBackground & Aim• More conformal radiotherapy More conformal radiotherapy accurate target definition accurate target definition
important important – Cervix Cancer Clinical Target Volume (CTV) definitions
variable
• Aim: Evaluate the variability in CTV delineation in Aim: Evaluate the variability in CTV delineation in preparation for a Phase 2 clinical trial being planned preparation for a Phase 2 clinical trial being planned by the Radiation Therapy Oncology Group (RTOG). by the Radiation Therapy Oncology Group (RTOG).
4F pelvis RT IMRT
![Page 13: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/13.jpg)
(13/10)
Methods & MaterialsMethods & Materials• Clinical Case: Clinical Case:
– 35yo G4P3 – clinical stage 1B poorly differentiated
adenocarcinoma of cervix. – No adenopathy or metastatic disease seen on
staging investigations. – MRI report confirms no parametrial, uterosacral
ligament or myometrial invasion. • MR & CT data sets made availableMR & CT data sets made available• Participants asked to contour: Participants asked to contour:
– GTV– Cervix (if seen)– Uterus– Upper vagina (3cm)– Parametria
• Online (ITC RRT; Washington U) or on Online (ITC RRT; Washington U) or on participantparticipant’’s treatment planning software.s treatment planning software.
Fig 1. Sample images (sagittal & axial) from clinical case. Figure 1
![Page 14: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/14.jpg)
(14/10)
ResultsResults
StructureStructureSensitivitySensitivity
(Avg(Avg±SD)±SD)
SpecificitySpecificity(Avg(Avg±SD)±SD)
Kappa Kappa measuremeasure**
GTVGTV 0.840.84±0.14±0.14 0.960.96±0.04±0.04 0.680.68§§
CervixCervix 0.550.55±0.24±0.24 0.980.98±0.03±0.03 0.420.42§§
UterusUterus 0.680.68±0.22±0.22 0.970.97±0.03±0.03 0.570.57§§
VaginaVagina 0.580.58±0.13±0.13 0.990.99±0.01±0.01 0.530.53§§
ParametriaParametria 0.480.48±0.27±0.27 0.990.99±0.02±0.02 0.420.42§§
*corrected for chance §p-value <0.0001
• 19 participants contoured on axial MR images
•Sagittal MR & axial CT images available for reference
![Page 15: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/15.jpg)
(15/10)
ResultsResults
Kappa measure
Level of Agreement
0.81 - 1.000.81 - 1.00 Almost perfectAlmost perfect
0.61 - 0.800.61 - 0.80 SubstantialSubstantial
0.41 - 0.600.41 - 0.60 ModerateModerate
0.21 - 0.400.21 - 0.40 FairFair
0.01 - 0.200.01 - 0.20 SlightSlight
0.000.00 No agreement No agreement above chanceabove chance
-1.00-1.00 Complete Complete disagreementdisagreement
GTVGTV
Kappa = 0.68Kappa = 0.68
CervixCervix
Kappa = 0.42Kappa = 0.42
UterusUterus
Kappa = 0.57Kappa = 0.57
VaginaVagina
Kappa = 0.53Kappa = 0.53
ParametriaParametria
Kappa = 0.42Kappa = 0.42
(Landis JR, Koch GG. 1977)
![Page 16: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/16.jpg)
(16/10)
Results – 95% agreementResults – 95% agreement
GTVGTV
CervixCervix
VaginaVagina
UterusUterus
ParametriaParametriaCTV CTV
consensusconsensusCTV CTV
consensusconsensus
![Page 17: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/17.jpg)
• Specificity was high Specificity was high –Greater certainty about what should NOT
be included in CTV• Sensitivity was moderateSensitivity was moderate
–Greater difficulty determining the interface between various CTV components
• Challenging case: Challenging case: –Extreme ante-version of uterus –Ability to view sagittal images
• Substantial organ motion, deformation and Substantial organ motion, deformation and tumor regression for this site is not tumor regression for this site is not addressed in this work.addressed in this work.
![Page 18: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/18.jpg)
Parametria & change depending on volume of bladder
Courtesy of Karen Lim, Princess Margaret Hospital
![Page 19: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/19.jpg)
Assessment of location
• Ultrasound: imprecise
• kV imaging: rough estimate
• Cone beam CT: Intensive resource utilization
![Page 20: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/20.jpg)
IMRT/IGRT
• No clear outcome benefit in cervix ca or postop endometrial cancer
• Greatest potential benefit in nodal recurrence
![Page 21: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/21.jpg)
• May be dangerous due to need to include presacral nodes (mesorectal), uterosacral ligaments, and internal iliac nodes
• Rectal filling may vary
• NOT recommended
Rectal Sparing
![Page 22: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/22.jpg)
Definitive Contouring
• Consider a CTV that includes the uterus/cervix, parametrial tissues, vagina, and pelvic nodes, (common, internal & external, obturator, and iliacs, presacral nodes) with exclusion only of small bowel and some bladder and sigmoid
• Need @3cm margin on CTV for uterine PTV; 1.5 cm on CTV cervix for PTV
• No sparing of rectum or posterior bladder; potential sparing of small bowel with para-aortic nodal field
![Page 23: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/23.jpg)
Is IMRT/IGRT Ready for Prime Time in the Therapy of Cervical
Cancer?• For post-operative therapy – maybe
– Still need prospective verification of targets (RTOG 0418)
– Rectal movement remains a concern• For definitive therapy in cervical cancer – No
• Organ motion and volume changes during therapy remain a significant issue
• For para-aortic nodes, spare small bowel• Re-irradiation – unknown sequelae
![Page 24: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/24.jpg)
PET/CT Fusion Nodal Contour
IMRT for Nodal boost 54-65 Gy
![Page 25: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/25.jpg)
Post-operative PAN positiveno residual LN (45 Gy)
![Page 26: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/26.jpg)
![Page 27: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/27.jpg)
![Page 28: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/28.jpg)
![Page 29: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/29.jpg)
![Page 30: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/30.jpg)
![Page 31: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/31.jpg)
![Page 32: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/32.jpg)
![Page 33: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/33.jpg)
![Page 34: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/34.jpg)
![Page 35: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/35.jpg)
Vaginal recurrence
• Pelvic LN+• 45 Gy region• 65 Gy pelvic mass
and LN+
![Page 36: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/36.jpg)
![Page 37: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/37.jpg)
![Page 38: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/38.jpg)
![Page 39: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/39.jpg)
![Page 40: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/40.jpg)
SBRT as a boost
• Node recurrence, sidewall recurrence
• Higher normal tissue dose
• Long term complication rateHDR SBRT
![Page 41: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/41.jpg)
SBRT for Recurrent Cervix Ca
Dose FailureDeodato et al.Oncol Repo 22:415-419
1 pt w vaginal recurrence
30 Gy/6 fractions 7/11 FAIL2 Grade 4 fistulae1 Grade 4 ileus
Guckenberger et al. Rad onc 94:53-59 7 central recurrences
50 Gy + 5 Gy x 3 Fx 7/10 FAIL
![Page 42: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/42.jpg)
HDR SBRT
SBRTHDR
Images courtesy of A. Damato
![Page 43: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/43.jpg)
Post-operative IMRT: RTOG Atlaswww.rtog.org
![Page 44: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/44.jpg)
Image-Based Brachytherapy for Gynecologic Cancers
![Page 45: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/45.jpg)
Can IMRT replace brachytherapy? NOCan IMRT replace
brachytherapy? NO
• Complex internal organ motion– Brachy fixed to target
• Tumor response• The proximity of
critical structures leaves little room for error in EBRT planning
• Complex internal organ motion– Brachy fixed to target
• Tumor response• The proximity of
critical structures leaves little room for error in EBRT planning
After 45 Gy EBRT
![Page 46: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/46.jpg)
Volume Based TreatmentVolume Based Treatment
Moves with patientMoves with patient Does not move with patientDifficult to adjust with responseDoes not move with patientDifficult to adjust with response
BrachytherapyBrachytherapy IMRTIMRT
![Page 47: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/47.jpg)
Brachytherapy is Necessary• Tumor control probability correlated
with RT dose and cervix ca volume Fletcher, Shukovsky J Radiol Electrol 56:383-400, 1975
External beam only External Beam + brachytherapy
4 y PC4 y SurvivalLanciano JROBP 20:95, 1991
45%19%
67%46%
Local Control Montana Cancer 57:148, 1986
40% 52%
![Page 48: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/48.jpg)
Ultrasound
• Suspected uterine preforation
• Retroverted uterus• Absence of
endocervical canal• Extreme
anteversion of uterus
![Page 49: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/49.jpg)
Viswanathan ASTRO 9/25/08
Posterior placement
Proper placement
What might appear acceptable on Xray, may not be acceptable in 3D
![Page 50: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/50.jpg)
CT-Based Brachytherapy
• CT-simulators available in most radiation oncology departments
• Easy transition from film-based dosimetry to CT-based dosimetry
![Page 51: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/51.jpg)
MRI/CT Compatible Applicators •MRI/CT compatible applicators inserted brachytherapy suite
Secure fixation of applicator within pt
(vaginal packing and perineal bar)
![Page 52: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/52.jpg)
CT-Based Brachytherapy
• Rule out uterine perforation
![Page 53: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/53.jpg)
CT-Based Brachytherapy• Assess location and position of
applicator relative to the uterus
![Page 54: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/54.jpg)
bladder
rectum
Use of ContrastDrain bladder
Clamp foley
60 cc of 10% hypaque contrast into bladder
50 cc barium rectum
![Page 55: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/55.jpg)
Organs at Risk:Bladder, Rectum, Sigmoid, Small
Bowel
BladderRectum
![Page 56: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/56.jpg)
CT based targets vs. MR-imaging
• GTV – T2 bright areas
• HR-CTV – cervix + visible/palpable disease at brachy
• IR-CTV – 1 cm margin around HR-CTV + initial sites of involvement
• CT definitions:
• CT-CTV – 3cm above applicator
• CE (Clinical exam)-CTV – includes vaginal extension
GTVHR CTV
IR CTV
GYN GEC ESTRO Recommendations (I) Radioth.Oncol. 2005, 74:235-245
![Page 57: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/57.jpg)
#Mode of
treatmentSt
Imaging During
BT
Median Follow
up (years)
Local control
(%)
Disease specific
Survival (%)
Overall Survival (%) Grade 3-4
Toxicity
705IB-IIIB
2
76 BT and Sx Xray 92 87 95 14.6
89 BT and Sx CT 100 90 96 8.9
142ChRT/BT
and SXXray 85 73 85 12.5
163ChRT/BT
and SXCT 93 77 86 8.8
118 ChRT/BT Xray 74 55 65 22.7
117 ChRT/BT CT 78.5* 60 74 2.6
CT Gyne Brachy Improves Outcomes:Prospective French STIC trial
![Page 58: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/58.jpg)
Viswanathan ASTRO 9/25/08
Diagnosis
MRI 1st fraction
External beam response
![Page 59: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/59.jpg)
HR-CTV
Rectum
CT
MR
Bladder
Similar OAR contoursno significant differences
Viswanathan et al. Int J Radiat Oncol Biol, 2005
• Width larger on CT – Good for covering
parametrium– No issues with toxicity
• Height not determined on CT unless referring to an MRI– Estimate 3 cm on average– Always treat entire length
of tandem
![Page 60: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/60.jpg)
Viswanathan ASTRO 11/3/09
Brachytherapy exemplifies…• Point versus volume
![Page 61: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/61.jpg)
Viswanathan ASTRO 11/3/09
3D Brachytherapy Outcomes
• 145 patients• Historical
comparison• Significant ↑
– OS 53 to 64%– CSS 62 to 74%– Tumors > 5cm
• OS 28 to 58%
Pötter et al. Rad Oncol 2007
![Page 62: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/62.jpg)
Physical-Biological Documentation of Gynecologic HDR BT
EQD2: BED/1.2
BED= nd(1+d/alpha-beta ratio)
BED: 5.5Gy x 5 (1 + 5.5/10)=42.625 Gy
EQD2: 42.625/1.2 = 35.5 Gy
![Page 63: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/63.jpg)
Viswanathan ASTRO 9/25/08
Plan for each HDR fraction required
Radioth Oncol 81:269, 2006
![Page 64: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/64.jpg)
Viswanathan ASTRO 11/3/09
HDR/PDR Treatment Planning:
Dose OptimizationStandard plan Optimized plan
![Page 65: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/65.jpg)
Viswanathan ASTRO 11/3/09
Practical implementation• Standard plan mimics LDR loadings• Optimization superiorly – sigmoid/small bowel
– Treat entire tandem length +/- 1cm
• Optimization posteriorly - rectum– Watch dwell weight changes carefully
• Set to local rather than global• Change individual positions rather than regions
• Optimization anteriorly – bladder– Very high doses; no risk to tumor coverage
• “Over-coverage” versus “underdosage”
![Page 66: Igrt for cervical cancer feb 8 2013 920 a cancer ci 2013](https://reader038.vdocuments.us/reader038/viewer/2022103016/555d28b5d8b42ab2228b580e/html5/thumbnails/66.jpg)
Summary
• IMRT – CAUTION– OK for nodal boost, PAN treatment,
recurrence– Not standard for primary cervical ca– NOT a substitute for brachytherapy– Use image guidance with brachytherapy to
reduce toxicity and maximize tumor coverage